anti-inhibitor coagulant complex (activated prothrombin complex concentrate)
Trade name: Autoplex-T
Biologicalapproved
Approved
Dec 21, 1979
Clinical trial activity
15 trials · 15 clinical orgs · 1 marketing orgs
Phase 1
1
Phase 2
8
Phase 3
7
Phase 4
4
Earliest trial started Jul 1, 2000 (NCT00166309)
Timeline
Indications
Approved for
Mechanism of action
- ThrombinImmunity, passive
F2 immunity, passive
Approval history
- approvedDec 21, 1979
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSCS849DUN3M ↗
- ChEMBLCHEMBL4297953 ↗
- ChEMBLCHEMBL2108764 ↗
Also known as
- activated prothrombin complex
- aicc complex
- anti-inhibitor coagulant complex
- anti-inhibitor coagulant complex
- anti-inhibitor coagulant complex
- antiinhibitor coagulant complex
- antiinhibitor coagulant complex
- anti-inhibitory coagulant complex
- apcc
- autoplex
- factor eight inhibitor bypassing activity
- factor viii bypassing fraction
- factor viii inhibitor bypassing activity
- factor viii inhibitor bypassing activity
- factor viii inhibitor bypassing fraction
- factor viii inhibitor bypassing fraction
- feiba
- feiba
- feiba-vh
- prothrombin complex, activated
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07032792 | Phase 2 | Jun 30, 2025 | Northwell Health |
| NCT05156983 | Phase 3 | Mar 21, 2022 | Takeda |
| NCT04563520 | Phase 3 | Dec 31, 2021 | Emory University, Takeda |
| NCT05020483 | Phase 2 | Oct 28, 2021 | Mayo Clinic |
| NCT04867837 | Phase 3 | Sep 1, 2021 | Octapharma |
| NCT04205175 | Phase 4 | Feb 29, 2020 | Children's Hospital Los Angeles, Takeda |
| NCT03417102 | Phase 3 | Mar 22, 2018 | Genzyme, Sanofi |
| NCT02764489 | Phase 3 | Jan 1, 2017 | Baxalta |
| NCT02577614 | Phase 1 | Feb 1, 2016 | Oregon Health and Science University |
| NCT01800435 | Phase 4 | Oct 1, 2011 | Osaka University |
| NCT00851721 | Phase 3 | Mar 1, 2009 | Baxalta |
| NCT00284193 | Phase 4 | Jan 1, 2005 | Tel Aviv University |
| NCT00221195 | Phase 2/Phase 3 (Phase 3) | Jun 1, 2003 | Tulane University |
| NCT00108797 | Phase 4 | Sep 1, 2001 | Novo Nordisk |
| NCT00166309 | N/A | Jul 1, 2000 | Lund University |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (15)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 3 | 1 | 2 | 2020 |
| Baxalta | For profit | 2 | 2 | 1 | 2009 |
| Children's Hospital Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Genzyme | For profit | 1 | 1 | 1 | 2018 |
| Lund University | Academic/Hospital | 1 | 1 | 1 | 2000 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Northwell Health | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Novo Nordisk | For profit | 1 | 1 | 1 | 2001 |
| Octapharma | For profit | 1 | 1 | 1 | 2021 |
| Oregon Health and Science University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Osaka University | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Sanofi | For profit | 1 | 0 | 1 | 2018 |
| Tel Aviv University | Academic/Hospital | 1 | 1 | 1 | 2005 |
| Tulane University | Academic/Hospital | 1 | 1 | 1 | 2003 |
15 organizations
Page 1 / 1